Sep 20, 2016

14 Ways Your Donation Helps Real People

When you donate to a worthy cause, you want to know exactly how that contribution helps real people.
Sep 16, 2016

What We’re Learning from Alzheimer’s Research and How Biomarkers May Help

Hope and expectation have never met more frequently with disappointment in clinical trial research for Alzheimer’s disease. But the question is, why? 

Sep 08, 2016

AbbVie Leads Industry in Dow Jones Sustainability World Index

AbbVie is the industry leader in Dow Jones Sustainability World Index with the highest score of 34 biotechnology companies.
Sep 02, 2016

The Surprising Reasons People Don’t Do What the Doctor Ordered

Half of all people with chronic diseases don’t take their medications as directed. Finding out why is only half the battle.

Aug 05, 2016

World-Renowned Soccer Star Tackles a New Challenge

For soccer star Brandi Chastain, having a game plan was second nature, until last year when she had to tackle a different type of plan.

Jul 29, 2016

Second Quarter 2016 Financial Results

Double-digit revenue and adjusted EPS growth for the 6th consecutive quarter
Jul 25, 2016

How a World Free from Viral Hepatitis is Possible

On the heels of World Hepatitis Day, advocacy leader Raquel Peck reflects on what viral hepatitis elimination means, the significance of 2030 and her Haribo candy love. 

Jul 18, 2016

How to Overcome the Blood-Brain Barrier to Deliver New Medicines

The brain’s protection barrier prevents medicines from getting in, but new approaches are finding ways to bust through and treat central nervous system diseases.



Sep 23, 2016

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

NORTH CHICAGO, Ill., Sept. 23, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) treatment. In the Phase 3b GARNET study, 98 percent (n=160/163) of previously untreated patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis achieved sustained virologic response rates at 12 weeks post-treatment (SVR12).1 These data were presented today at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure, in Paris, France and included in the newly published 'EASL Recommendations on Treatment of Hepatitis C.' VIEKIRAX + EXVIERA is currently approved in the European Union for GT1b patients without cirrhosis or with compensated cirrhosis for 12 weeks.

Sep 15, 2016

New Data Presented At ECTRIMS Reinforce Efficacy of ZINBRYTA™ (daclizumab) and Support Long-Term Safety Profile

Cambridge, Mass. & North Chicago, Ill. – September 15, 2016 – A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTATM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX® (interferon beta-1a) intramuscular injection. The findings continue to support the positive impact of ZINBRYTA on NEDA status. Additional new interim data from the long-term extension study, EXTEND, further affirm ZINBRYTA’s efficacy on clinically meaningful measures of multiple sclerosis (MS) disease activity and provide additional information supporting ZINBRYTA’s safety profile. These results were presented by Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.
Sep 13, 2016

AbbVie Launches 2016 Thriving Student Scholarship Contest to Award Two Inspirational Students with Cystic Fibrosis $24,000 Each in Educational Funds

NORTH CHICAGO, Ill., Sept. 13, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the launch of the 2016 Thriving Student Scholarship Contest designed to grant $24,000 in educational funds to two exceptional students with cystic fibrosis (CF). Earlier this year, AbbVie selected 40 undergraduate and graduate students living with CF to each receive a $3,000 AbbVie CF Scholarship for the upcoming school year based on their academic excellence, extracurricular activities and creativity. These AbbVie CF Scholars now have the opportunity to earn the title of 2016 Thriving Undergraduate or Graduate Student, along with an additional $21,000 in scholarship funding.